CSI Market
Sign In | Register

Aligos Therapeutics Inc (ALGS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ALGS Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Aligos Therapeutics Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-24.54
Depreciation & amortization0.60
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation2.68
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-6.37
Operating Lease Right Of Use Asset Amortization Expense0.51
Derivative Gain Loss On Derivative Net-
Minority Interest Change In Redemption Value-
Increase Decrease In Right Of Use Assets-
Increase Decrease In Operating Lease Liabilities-0.83
Leasehold Improvement Directly Paid By The Landlord-
Right Of Use Asset Obtained In Exchange For Finance Lease Liability-
Market To Market Adjustment For Available For Sale Investments-
Increase Decrease In Contract With Customer Liability-
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable27.78
Increase (Decrease) in Accounts Payable2.45
Increase (Decrease) in Accrued Liabilities5.17
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital-0.99
Other Noncash Income (Expense)0.00
Other net0.49
Payments for (Proceeds from) Other Operating Activities-55.35
Discontinued operations0.00
Net Cash flow from Operating Activities-48.08
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments60.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Purchases Write Offs Of Property And Equipment-0.07
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Long-term Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-0.07
Discontinued operations0.00
Net Cash Flow from Investing Activities59.93
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.24
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.08
Payments On Deferred Offering Costs-
Finance Lease Principal Payments-0.06
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents18.41
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.16
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-48.08
Total Cash Flow12.01
4 historic quarters locked

Sign in to unlock the full Aligos Therapeutics Inc cash flow history.

Sign In Create Free Account

About Aligos Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-336851

Figures are derived from filed reports and may be restated. Historical data is subject to revision.